NO315408B1 - Anvendelse av imidazo[1,2-a]pyridin-3-acetamidderivater for terapeutisk behandling av neuropsykiatriske syndromer assosiert med disfunksjonav de sentraleområder av de basale ganglia - Google Patents
Anvendelse av imidazo[1,2-a]pyridin-3-acetamidderivater for terapeutisk behandling av neuropsykiatriske syndromer assosiert med disfunksjonav de sentraleområder av de basale ganglia Download PDFInfo
- Publication number
- NO315408B1 NO315408B1 NO19974603A NO974603A NO315408B1 NO 315408 B1 NO315408 B1 NO 315408B1 NO 19974603 A NO19974603 A NO 19974603A NO 974603 A NO974603 A NO 974603A NO 315408 B1 NO315408 B1 NO 315408B1
- Authority
- NO
- Norway
- Prior art keywords
- zolpidem
- disease
- patients
- pyridine
- parkinson
- Prior art date
Links
- NSJOHWXCJYNOSF-UHFFFAOYSA-N 2-imidazo[1,2-a]pyridin-3-ylacetamide Chemical class C1=CC=CN2C(CC(=O)N)=CN=C21 NSJOHWXCJYNOSF-UHFFFAOYSA-N 0.000 title claims description 6
- 210000004227 basal ganglia Anatomy 0.000 title description 16
- 230000001225 therapeutic effect Effects 0.000 title description 9
- 230000004064 dysfunction Effects 0.000 title description 2
- 206010071323 Neuropsychiatric syndrome Diseases 0.000 title 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical group N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 claims description 81
- 229960001475 zolpidem Drugs 0.000 claims description 79
- 208000018737 Parkinson disease Diseases 0.000 claims description 64
- 239000003814 drug Substances 0.000 claims description 40
- 206010012289 Dementia Diseases 0.000 claims description 25
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 19
- 208000011580 syndromic disease Diseases 0.000 claims description 18
- 206010034010 Parkinsonism Diseases 0.000 claims description 16
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 15
- 208000023105 Huntington disease Diseases 0.000 claims description 13
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 12
- 231100000867 compulsive behavior Toxicity 0.000 claims description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 6
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 4
- 208000018839 Wilson disease Diseases 0.000 claims description 4
- 208000013044 corticobasal degeneration disease Diseases 0.000 claims description 4
- 208000007431 neuroacanthocytosis Diseases 0.000 claims description 4
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 230000001054 cortical effect Effects 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 37
- 230000000694 effects Effects 0.000 description 34
- 230000006872 improvement Effects 0.000 description 30
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 28
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 27
- 210000001905 globus pallidus Anatomy 0.000 description 22
- 208000024891 symptom Diseases 0.000 description 20
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 description 16
- 208000007656 osteochondritis dissecans Diseases 0.000 description 16
- 210000003523 substantia nigra Anatomy 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 150000005232 imidazopyridines Chemical class 0.000 description 14
- 239000000902 placebo Substances 0.000 description 14
- 229940068196 placebo Drugs 0.000 description 14
- 229940049706 benzodiazepine Drugs 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 206010041349 Somnolence Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000003902 lesion Effects 0.000 description 11
- 230000002739 subcortical effect Effects 0.000 description 11
- 208000032140 Sleepiness Diseases 0.000 description 10
- 150000001557 benzodiazepines Chemical class 0.000 description 10
- 230000037321 sleepiness Effects 0.000 description 10
- JRTIDHTUMYMPRU-UHFFFAOYSA-N alpidem Chemical compound N1=C2C=CC(Cl)=CN2C(CC(=O)N(CCC)CCC)=C1C1=CC=C(Cl)C=C1 JRTIDHTUMYMPRU-UHFFFAOYSA-N 0.000 description 9
- 229950008673 alpidem Drugs 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 8
- 230000003371 gabaergic effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000003291 dopaminomimetic effect Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000004940 nucleus Anatomy 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 210000001103 thalamus Anatomy 0.000 description 7
- 102000004300 GABA-A Receptors Human genes 0.000 description 6
- 108090000839 GABA-A Receptors Proteins 0.000 description 6
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 206010001541 Akinesia Diseases 0.000 description 5
- 206010010219 Compulsions Diseases 0.000 description 5
- 241000557626 Corvus corax Species 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000002637 putamen Anatomy 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 4
- 208000027776 Extrapyramidal disease Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000000648 anti-parkinson Effects 0.000 description 4
- 239000000939 antiparkinson agent Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 210000001222 gaba-ergic neuron Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000001577 neostriatum Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000007958 sleep Effects 0.000 description 4
- 208000019116 sleep disease Diseases 0.000 description 4
- RRUSBIOGIXLJPM-UHFFFAOYSA-N 1-methyl-4-phenyl-4-propoxypiperidine Chemical compound C=1C=CC=CC=1C1(OCCC)CCN(C)CC1 RRUSBIOGIXLJPM-UHFFFAOYSA-N 0.000 description 3
- 206010006100 Bradykinesia Diseases 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 208000006083 Hypokinesia Diseases 0.000 description 3
- 206010029897 Obsessive thoughts Diseases 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 229960004046 apomorphine Drugs 0.000 description 3
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 210000001159 caudate nucleus Anatomy 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 3
- 229960003120 clonazepam Drugs 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 229940052760 dopamine agonists Drugs 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 239000003326 hypnotic agent Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 230000002295 serotoninergic effect Effects 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010008748 Chorea Diseases 0.000 description 2
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 2
- 241001573498 Compacta Species 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 101000618525 Homo sapiens Membrane transport protein XK Proteins 0.000 description 2
- 102100022472 Membrane transport protein XK Human genes 0.000 description 2
- 208000027382 Mental deterioration Diseases 0.000 description 2
- 206010027374 Mental impairment Diseases 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 2
- 208000002740 Muscle Rigidity Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 229940121985 Non-benzodiazepine hypnotic Drugs 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960004606 clomipramine Drugs 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000006998 cognitive state Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 210000005153 frontal cortex Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000001962 neuropharmacologic effect Effects 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- IBALRBWGSVJPAP-HEHNFIMWSA-N progabide Chemical compound C=1C(F)=CC=C(O)C=1C(=N/CCCC(=O)N)/C1=CC=C(Cl)C=C1 IBALRBWGSVJPAP-HEHNFIMWSA-N 0.000 description 2
- 229960002752 progabide Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000004281 subthalamic nucleus Anatomy 0.000 description 2
- 230000007428 synaptic transmission, GABAergic Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 2
- 229960003386 triazolam Drugs 0.000 description 2
- 230000001173 tumoral effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- YDHIMEXEGOCNHU-UHFFFAOYSA-N 2-pyridin-3-ylacetamide Chemical class NC(=O)CC1=CC=CN=C1 YDHIMEXEGOCNHU-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940086575 Glutamate release inhibitor Drugs 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021034 Hypometabolism Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000007873 MPTP Poisoning Diseases 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical class C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010048327 Supranuclear palsy Diseases 0.000 description 1
- 208000027522 Sydenham chorea Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- 229960000911 benserazide Drugs 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000007370 cognitive improvement Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000004908 diazepines Chemical class 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 description 1
- 230000008923 dopaminergic innervation Effects 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 210000004101 entopeduncular nucleus Anatomy 0.000 description 1
- 201000011384 erythromelalgia Diseases 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 1
- 229960004381 flumazenil Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- CGSFZSTXVVJLIX-UHFFFAOYSA-N n-desmethylzopiclone Chemical compound N1=CC(Cl)=CC=C1N1C(=O)C2=NC=CN=C2C1OC(=O)N1CCNCC1 CGSFZSTXVVJLIX-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 101150006061 neur gene Proteins 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 230000003565 oculomotor Effects 0.000 description 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002360 prefrontal effect Effects 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000003755 striatonigral degeneration Diseases 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000007497 verbal memory Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229960000820 zopiclone Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT95RM000223A IT1276522B1 (it) | 1995-04-07 | 1995-04-07 | Uso dello zolpidem per il trattamento terapeudico di sindromi neuropsichiatriche associate a disfunsione e di circuiti neurali dei |
PCT/IT1996/000063 WO1996031210A1 (en) | 1995-04-07 | 1996-04-02 | USE OF IMIDAZO[1,2-a]PYRIDINE-3-ACETAMIDE DERIVATIVES FOR THE THERAPEUTIC TREATMENT OF NEUROPSYCHIATRIC SYNDROMES ASSOCIATED WITH DISFUNCTION OF THE NEURAL CIRCUITS OF THE BASAL GANGLIA |
Publications (3)
Publication Number | Publication Date |
---|---|
NO974603D0 NO974603D0 (no) | 1997-10-06 |
NO974603L NO974603L (no) | 1997-11-24 |
NO315408B1 true NO315408B1 (no) | 2003-09-01 |
Family
ID=11403250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19974603A NO315408B1 (no) | 1995-04-07 | 1997-10-06 | Anvendelse av imidazo[1,2-a]pyridin-3-acetamidderivater for terapeutisk behandling av neuropsykiatriske syndromer assosiert med disfunksjonav de sentraleområder av de basale ganglia |
Country Status (25)
Country | Link |
---|---|
US (1) | US5891891A (cs) |
EP (1) | EP0819002B1 (cs) |
JP (1) | JP4049390B2 (cs) |
KR (1) | KR100425628B1 (cs) |
CN (1) | CN1198612C (cs) |
AR (1) | AR003414A1 (cs) |
AT (1) | ATE222763T1 (cs) |
AU (1) | AU707759B2 (cs) |
CA (1) | CA2217590C (cs) |
CZ (1) | CZ292020B6 (cs) |
DE (1) | DE69623271T2 (cs) |
DK (1) | DK0819002T3 (cs) |
EA (1) | EA000396B1 (cs) |
ES (1) | ES2182967T3 (cs) |
HU (1) | HUP9900733A3 (cs) |
IL (1) | IL117824A (cs) |
IT (1) | IT1276522B1 (cs) |
MX (1) | MX9707712A (cs) |
NO (1) | NO315408B1 (cs) |
NZ (1) | NZ304107A (cs) |
PL (1) | PL322647A1 (cs) |
PT (1) | PT819002E (cs) |
TW (1) | TW450816B (cs) |
WO (1) | WO1996031210A1 (cs) |
ZA (1) | ZA962711B (cs) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7632517B2 (en) * | 1997-10-01 | 2009-12-15 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing zolpidem |
US6333345B1 (en) | 1999-05-14 | 2001-12-25 | Sepracor, Inc. | Methods of using and compositions comprising N-desmethylzolpidem |
US6399621B1 (en) | 1999-08-10 | 2002-06-04 | American Cyanamid Company | N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto |
US20030091632A1 (en) * | 1999-08-26 | 2003-05-15 | Neurocrine Biosciences, Inc. | Controlled-release sedative-hypnotic compositions and methods related thereto |
US6485746B1 (en) | 2000-08-25 | 2002-11-26 | Neurocrine Biosciences, Inc. | Controlled-release sedative-hypnotic compositions and methods related thereto |
US6384221B1 (en) | 1999-09-02 | 2002-05-07 | Neurocrine Biosciences, Inc. | Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto |
AU5066101A (en) * | 2000-04-13 | 2001-10-30 | Synthon B.V. | Modified release formulations containing a hypnotic agent |
DE20122435U1 (de) * | 2000-04-24 | 2005-10-06 | Teva Pharmaceutical Industries Ltd. | Mikronisiertes Zolpidem-Hemitartrat |
DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
DE10117183A1 (de) * | 2001-04-05 | 2002-10-10 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel |
GB0311457D0 (en) * | 2003-05-19 | 2003-06-25 | Sciencom Ltd | New therapeutic use |
JP2008506630A (ja) * | 2003-05-19 | 2008-03-06 | サイエンコム・リミテッド | ゾルピデムの更なる治療的使用 |
DE10334187A1 (de) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
DE10334188B4 (de) | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
PL1691811T3 (pl) | 2003-12-11 | 2014-12-31 | Sunovion Pharmaceuticals Inc | Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji |
DE10361258A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
DE602005018763D1 (de) | 2004-02-18 | 2010-02-25 | Sepracor Inc | Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität |
DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
DE602006008339D1 (en) * | 2005-11-18 | 2009-09-17 | Synhton B V | Zolpidemtabletten |
GB2443928A (en) * | 2006-11-08 | 2008-05-21 | Regen Therapeutics Plc | Transdermal pharmaceutical composition comprising Zolpidem |
GB0809936D0 (en) * | 2008-05-30 | 2008-07-09 | Regen Therapeutics Plc | Therapeutic use of zolpidem |
WO2017214442A1 (en) | 2016-06-08 | 2017-12-14 | President And Fellows Of Harvard College | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, rett syndrome, and fragile x syndrome |
US11434244B2 (en) | 2018-05-29 | 2022-09-06 | President And Fellows Of Harvard College | Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2492382A1 (fr) * | 1980-10-22 | 1982-04-23 | Synthelabo | Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique |
US5032595A (en) * | 1989-11-24 | 1991-07-16 | Fidia-Georgetown Institute For The Neurosciences | Method of stimulating steroidogenesis with alpidem |
US5206382A (en) * | 1991-06-27 | 1993-04-27 | Fidia Georgetown Institute For The Neurosciences | Indole derivatives, pharmaceutical compositions and methods of treating neurological and psychiatric disorders |
-
1995
- 1995-04-07 IT IT95RM000223A patent/IT1276522B1/it active IP Right Grant
-
1996
- 1996-04-02 HU HU9900733A patent/HUP9900733A3/hu unknown
- 1996-04-02 AU AU51200/96A patent/AU707759B2/en not_active Ceased
- 1996-04-02 NZ NZ304107A patent/NZ304107A/xx not_active IP Right Cessation
- 1996-04-02 PT PT96907656T patent/PT819002E/pt unknown
- 1996-04-02 WO PCT/IT1996/000063 patent/WO1996031210A1/en active IP Right Grant
- 1996-04-02 CA CA002217590A patent/CA2217590C/en not_active Expired - Lifetime
- 1996-04-02 DE DE69623271T patent/DE69623271T2/de not_active Expired - Lifetime
- 1996-04-02 KR KR1019970707107A patent/KR100425628B1/ko not_active IP Right Cessation
- 1996-04-02 CN CNB961937815A patent/CN1198612C/zh not_active Expired - Fee Related
- 1996-04-02 EA EA199700308A patent/EA000396B1/ru not_active IP Right Cessation
- 1996-04-02 MX MX9707712A patent/MX9707712A/es unknown
- 1996-04-02 US US08/930,644 patent/US5891891A/en not_active Expired - Lifetime
- 1996-04-02 JP JP53016596A patent/JP4049390B2/ja not_active Expired - Fee Related
- 1996-04-02 ES ES96907656T patent/ES2182967T3/es not_active Expired - Lifetime
- 1996-04-02 AT AT96907656T patent/ATE222763T1/de active
- 1996-04-02 DK DK96907656T patent/DK0819002T3/da active
- 1996-04-02 EP EP96907656A patent/EP0819002B1/en not_active Expired - Lifetime
- 1996-04-02 PL PL96322647A patent/PL322647A1/xx unknown
- 1996-04-02 CZ CZ19973167A patent/CZ292020B6/cs not_active IP Right Cessation
- 1996-04-03 IL IL11782496A patent/IL117824A/xx not_active IP Right Cessation
- 1996-04-04 ZA ZA962711A patent/ZA962711B/xx unknown
- 1996-04-08 AR ARP960102094A patent/AR003414A1/es unknown
- 1996-04-15 TW TW085104484A patent/TW450816B/zh not_active IP Right Cessation
-
1997
- 1997-10-06 NO NO19974603A patent/NO315408B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO315408B1 (no) | Anvendelse av imidazo[1,2-a]pyridin-3-acetamidderivater for terapeutisk behandling av neuropsykiatriske syndromer assosiert med disfunksjonav de sentraleområder av de basale ganglia | |
US11083713B2 (en) | Treatment of progressive neurodegenerative disease with ibudilast | |
Nguyen et al. | Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders | |
Manton et al. | Declining prevalence of dementia in the US elderly population | |
Post et al. | Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response | |
Lucas et al. | Effects of the acute administration of caffeine in patients with schizophrenia | |
Ashford | Treatment of Alzheimer’s disease: trazodone, sleep, serotonin, norepinephrine, and future directions | |
Kennedy et al. | A current review of olanzapine's safety in the geriatric patient: from pre‐clinical pharmacology to clinical data | |
Ghoge et al. | Cerebrovascular diseases and depression | |
JP2020512390A (ja) | シヌクレイノパチーを処置するための組成物および方法 | |
Fabbrini et al. | Excessive daytime somnolence in Parkinson’s disease. Follow-up after 1 year of treatment | |
Jenike et al. | Somatic treatments for obsessive-compulsive disorders | |
AU716972B2 (en) | Method for treating bipolar disorder | |
US20030045539A1 (en) | Cabergoline and pramipexole: new uses and combinations | |
Mann et al. | Malignant catatonia | |
Morita | Alex Eischeid, MD Hokuto Morita, MD Michel Medina, MD Kathleen L. Poston, MD, MS | |
Schapira et al. | The medical management of Parkinson’s disease | |
Cummings | Morgan L. Levy, MD Jeffrey L. Cummings, MD | |
YARYURA-TOBIAS et al. | HN BHAGAVAN | |
WO2008100422A1 (en) | Compositions comprising mkc-733 (pumosetrag) useful for treating irritable bowel syndrome | |
Frucht et al. | Malignant Catatonia | |
Dimachkie et al. | 37 Primary and Inflammatory Muscle Disorders in the Elderly | |
Barton et al. | Treatment of Chorea | |
MXPA99001029A (en) | Method for treating bipolar disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |